AbOliGo

Aboligo email format

Verified email-pattern data for Aboligo is currently limited. You can still use the company insights and contact sections below.
AbOliGo (Cambridge UK, founded 2024) is developing a revolutionary platform for rapid, small-scale production of antibody-oligonucleotide conjugates (AOCs), addressing a critical bottleneck in multiplexing. AOCs are transformative tools that combine antibodies' exquisite targeting specificity with oligonucleotides' properties - DNA amplification and molecular barcoding, enabling unlimited multiplexing. However, while there are approximately 7 million commercially available antibodies, only ~0.03% are offered as AOCs. Recognizing the growing demand for AOCs, we aim to innovate and re-imagine the manufacturing process through three key technological advancements: Scale - A novel conjugation methodology that enables production at µg scale. Quality – Develop a QC quantitative release criteria, guaranteeing batch consistency. Fast – Manufacture and deliver AOCs from a large portfolio within days.
Looking for a particular AbOliGo employee's phone or email?

Aboligo Questions

Explore related pages

Related company profiles:

Top AbOliGo Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant